While the numbers are eye opening..... chronic inflamation in 11 of 12 cases, calcification (3/12) product degeneration (9/12) necrosis !!!!! (5/12) and calcification (3/12).. the report identified that 12 of 532 patients had product explanted.....just 2.3% of cases. Product seemed to work for the vast majority.... but the 2.3 % is one patient in 43. Two issues. Who wants to risk being pt no 43??????? And....is it not the product being unsuitable or...the individual patient. Could be that certain patients are sensitive to cormatrix and CC is the product for patients at high risk of reaction. Sub category of patients CC can target perhaps without treading on toes.
However there are risks with in medicine and surgery but 1in 43 seems a tad high.
Just my two cents worth.
AHZ Price at posting:
6.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)